DNA Methylation Modification Regulator-Mediated Molecular Clusters and Tumor Metabolic Characterization in Prostate Cancer

Figure 6

The prognostic value of DMS. (a) Kaplan–Meier curves for low and high DMS groups in the meta cohort. Log-rank test, . (b) Kaplan–Meier curves for low and high DMS group in the TCGA cohort. Log-rank test, . (c) The ROC analysis of DMS in the meta cohort. AUC = 0.710, 0.667, and 0.640 at 1, 3, and 5 years. (d) The ROC analysis of DMS in the TCGA cohort. AUC = 0.686, 0.734, and 0.685 at 1, 3, and 5 years. (e) The meta-analysis of the DMS’s HR in six cohorts. (f) The nomogram based on DMS and clinical variates. (g) Concordance index of the nomogram in the meta cohorts. (h) The ROC analysis of nomogram in the meta (training) cohort. AUC = 0.763, 0.710, and 0.688 at 1, 3, and 5 years. (i) The ROC analysis of nomogram in the TCGA (validation) cohort. AUC = 0.779, 0.782, and 0.745 at 1, 3, and 5 years.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)